Howland Capital Management LLC Sells 2,878 Shares of Thermo Fisher Scientific Inc. $TMO

Howland Capital Management LLC reduced its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 4.0% during the second quarter, HoldingsChannel.com reports. The firm owned 69,813 shares of the medical research company’s stock after selling 2,878 shares during the quarter. Thermo Fisher Scientific makes up about 1.3% of Howland Capital Management LLC’s portfolio, making the stock its 19th largest holding. Howland Capital Management LLC’s holdings in Thermo Fisher Scientific were worth $35,034,000 at the end of the most recent quarter.

Other large investors have also added to or reduced their stakes in the company. Assetmark Inc. boosted its holdings in shares of Thermo Fisher Scientific by 22.9% during the fourth quarter. Assetmark Inc. now owns 37,654 shares of the medical research company’s stock valued at $21,819,000 after acquiring an additional 7,023 shares during the period. North Dakota State Investment Board acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter worth about $7,505,000. Boston Trust Walden Corp lifted its position in Thermo Fisher Scientific by 9.7% in the 4th quarter. Boston Trust Walden Corp now owns 43,973 shares of the medical research company’s stock valued at $25,480,000 after purchasing an additional 3,873 shares during the last quarter. Xponance LLC boosted its stake in Thermo Fisher Scientific by 8.1% during the 4th quarter. Xponance LLC now owns 59,295 shares of the medical research company’s stock valued at $34,358,000 after purchasing an additional 4,436 shares during the period. Finally, Merit Financial Group LLC increased its stake in shares of Thermo Fisher Scientific by 34.0% in the fourth quarter. Merit Financial Group LLC now owns 15,504 shares of the medical research company’s stock valued at $8,984,000 after purchasing an additional 3,934 shares during the period. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In related news, COO Gianluca Pettiti sold 400 shares of the stock in a transaction that occurred on Monday, July 27th. The shares were sold at an average price of $565.00, for a total transaction of $226,000.00. Following the completion of the sale, the chief operating officer directly owned 24,651 shares of the company’s stock, valued at $13,927,815. This represents a 1.60% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction that occurred on Friday, August 7th. The stock was sold at an average price of $584.81, for a total transaction of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at approximately $1,734,546.46. This trade represents a 12.40% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 26,553 shares of company stock valued at $15,343,589 over the last quarter. Company insiders own 0.33% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TMO shares. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $653.00 to $639.00 and set an “outperform” rating for the company in a research report on Friday, April 24th. KeyCorp reaffirmed an “overweight” rating on shares of Thermo Fisher Scientific in a research note on Tuesday, May 26th. HSBC lowered Thermo Fisher Scientific from a “buy” rating to a “hold” rating and reduced their price target for the stock from $670.00 to $540.00 in a research report on Wednesday, June 3rd. Barclays raised their price target on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, July 24th. Finally, Evercore set a $570.00 price objective on shares of Thermo Fisher Scientific in a report on Monday, July 6th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and six have issued a Hold rating to the company’s stock. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $619.41.

Thermo Fisher Scientific Stock Performance

TMO opened at $603.20 on Thursday. The business has a 50 day moving average price of $524.79 and a two-hundred day moving average price of $509.23. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The company has a market capitalization of $223.03 billion, a price-to-earnings ratio of 32.45, a price-to-earnings-growth ratio of 2.46 and a beta of 0.85. Thermo Fisher Scientific Inc. has a 1-year low of $435.27 and a 1-year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO) last issued its quarterly earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The company had revenue of $11.99 billion for the quarter, compared to analysts’ expectations of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The firm’s revenue for the quarter was up 10.5% on a year-over-year basis. During the same period last year, the firm earned $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Research analysts predict that Thermo Fisher Scientific Inc. will post 25.12 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be given a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.